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Abstract 
Purpose:  NaCl has proven to be an effective bitterness inhibitor, but the reason remains 
unclear.  The purpose of this study was to examine the influence of a variety of cations 
and anions on the bitterness of selected oral pharmaceuticals and bitter taste stimuli: 
pseudoephedrine, ranitidine, acetaminophen, quinine, and urea.  
Method:  Human psychophysical taste evaluation using a whole mouth exposure 
procedure was used. 
Results:  The cations (all associated with the acetate anion) inhibited bitterness when 
mixed with pharmaceutical solutions to varying degrees.  The sodium cation significantly 
(p<0.003) inhibited bitterness of the pharmaceuticals more than the other cations.  The 
anions (all associated with the sodium cation) also inhibited bitterness to varying degrees.  
With the exception of salicylate, the glutamate and adenosine monophosphate anions 
significantly (p<0.001) inhibited bitterness of the pharmaceuticals more than the other 
anions.  Also, there were several specific inhibitory interactions between ammonium, 
sodium and salicylate and certain pharmaceuticals.   
Conclusions:  We conclude that sodium was the most successful cation and glutamate 
and AMP were the most successful anions at inhibiting bitterness.  Structure forming and 
breaking properties of ions, as predicted by the Hofmeister series, and other physical-
chemical ion properties failed to significantly predict bitterness inhibition.   
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Introduction 
Excessive bitterness of the active compounds in oral liquid formulations is a 
major taste problem facing the pharmaceutical industry.  Bitterness of formulations can 
influence pharmaceutical selection by physicians and patients and affect compliance with 
prescribed regimens (1, 2).  Consequently, many methods to inhibit or block bitterness, 
both chemical and physical, have been employed.  A few examples are: the addition of 
sweeteners, lipids and emulsifiers, carbohydrates, proteins and flavors, and the 
encapsulation of the active compound (3); none of these methods is fully successful.  
Moreover, the problem of excessive bitterness in oral liquid formulations is a particularly 
pressing issue given the recent Federal requirement for pediatric formulations of 
pharmaceuticals to be produced.  Oral liquid dosage of pharmaceuticals, as opposed to 
pills or tablets, is the most tolerated form of delivery for infants, children and adult 
patients with difficulty swallowing solids.  
It is our opinion that the bitter taste of pharmaceuticals is an ongoing formulation 
problem in part because the transduction mechanisms for bitter taste are complex and not 
fully elucidated.  If we had a full understanding of bitter taste transduction, we should be 
able to decrease bitter taste perception by affecting selected transduction mechanisms.  
Recently, up to 80 putative G-protein-coupled bitter receptors (4--6) have been identified.  
In addition to multiple trans-membrane receptors, there are other means of activating 
bitter taste signal cascades, such as blocking or opening ion channels/pumps (e.g., 
quinine hydrochloride) (7) and direct activation of a G-proteins or enzymes (e.g., caffeine 
(8)) (for a review of bitter taste transduction pathways see Dulac(9), Brand(10), and 
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Spielman (11, 12)).  Given the potential diversity in bitter taste transduction sequences, it 
is unlikely that a single, universal, bitter blocker will be discovered.  Thus, the problem 
of how to suppress bitterness by physiological-chemical interactions continues to be 
unresolved. 
Certain ions, however, have been shown to suppress bitterness well.  Sodium is 
known to selectively inhibit the bitterness of specific compounds (13--16).  In this study, 
we systematically examined the influence of five cations on bitter pharmaceuticals to 
determine if the sodium cation is unique or if bitterness inhibition is a property shared 
with other cations.  In addition to the cations, we investigated the influence of anions on 
bitterness.  In this study we compare 12 anions, including known bitterness inhibitors, 
adenosine monophosphate (AMP) (17) and glutamate (18), to determine the degree to 
which anions possess bitterness inhibiting properties beyond those of the cations.   
While there has been no systematic study investigating the influences of a variety 
of salts on bitter taste perception, there is a large body of published research on the 
physical-chemical properties of salts.  Much of this research concerns salts in the 
Hofmeister series (19) (Figure 1).  The Hofmeister series of salts are sequenced, in part, 
according to their electronegativity at moderate concentrations (10mM to 1M) and 
neutral pH, and their ability to alter the structure of pure water and/or proteins (for a 
review see Collins(20)).  We examined whether the chemical-bond making or bond 
breaking properties of cations and anions employed here, predicted their ability to inhibit 
bitter taste according to their ranking in the Hofmeister series.  
Three of the most common over-the-counter pharmaceuticals were used as bitter 
stimuli in this research: pseudoephedrine (bronchodilator), ranitidine (antiulcerative) and 
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acetaminophen (analgesic, antipyretic).  In addition, two older pharmaceuticals 
commonly used in bitter taste research, quinine-HCl (antimalerial), and urea (osmotic, 
diuretic), were employed in order to make comparisons with the existing taste literature. 
The overall aim of this research project was to discover which of these sets of 
cations and anions were most effective at inhibiting bitterness of the chosen 
pharmaceuticals, and, if possible, to infer why.     
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Methods 
Subjects:  Subjects between the ages of 20 and 35 were paid to participate after providing 
informed consent on an Institutional Review Board approved form.  All but one were 
employees of Monell Chemical Senses Center.  Seventeen subjects (mean age 26 ± 5 
years) participated in the intensity matching and cation experiment, and 14 subjects who 
participated in the cation experiment, (mean age 27 ± 4 years) were in the anion 
experiment.  The subjects were asked to refrain from eating, drinking or chewing gum for 
at least one hour prior to testing.   
 
Training:  Subjects were initially trained in the use of the Labeled Magnitude Scale 
(LMS) following standard published procedures (21, 22) except the top of the scale was 
described as the “strongest imaginable” sensation of any kind (23).  The LMS is a 
psychophysical tool that requires subjects to rate the perceived intensity along a vertical 
axis lined with adjectives: barely detectable=1, weak=5, moderate=16, strong=33, very 
strong=51, strongest imaginable=96; the adjectives are spaced semi-logarithmically, 
based upon experimentally determined intervals (21, 22) to yield ratio quality data.  The 
scale only shows adjectives not numbers to the subjects, but the experimenter receives 
numerical data from the computer program.   
Subjects were trained to identify each of the five taste qualities by presenting 
them with exemplars.  Salty taste was identified as the predominant taste quality from 
150mM NaCl, bitterness as the predominant quality from 0.05mM quinine-HCl, 
sweetness as the predominant quality from 300mM sucrose, sourness as the predominant 
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quality from 3mM citric acid, and savory the predominant quality from a mixture of 
100mM glutamic acid monosodium salt and 50mM inosine 5’-monophosphate.  To help 
subjects understand a stimulus could elicit multiple taste qualities, 300mM urea (bitter 
and slightly sour) and 50mM NH4Cl (salty, bitter, and slightly sour) were employed as 
training stimuli. 
 
Materials:  Ranitidine was purchased from ICN Pharmaceuticals, acetaminophen and 
pseudoephedrine were purchased from Aldrich.  Quinine-HCl was purchased from Fluka 
Chemika (Buchs, Switzerland) and urea was purchased from Sigma Chemical (St. Louis).  
All salts were of the highest purity available and were purchased from Sigma Chemicals; 
they were: monosodium glutamate (MSG), adenosine monophosphate sodium salt 
(NaAMP), sodium chloride (NaCl), sodium salicylate (NaSal), sodium gluconate 
(NaGlc), disodium glycerophosphate (Na2GP), disodium phosphate (Na2Phos), sodium 
propionate (NaProp), disodium sulfate (Na2SO4), sodium iodide (NaI), sodium acetate 
(NaAc), ammonium acetate (NH4Ac), magnesium acetate (MgAc), potassium acetate 
(KAc), calcium acetate (CaAc) and potassium iodide (KI).  The combined cation solution 
(COMAc) consisted of 20mM of each of the following salts: NaAc, NH4Ac, MgAc, KAc, 
and CaAc.  The combined anion (COM) solution consisted of 20mM of the following 
salts: MSG, NaCl, NaSal, NaGlc, and NaI.   
All solutions were prepared with deionized (di) Millipore™ filtered water and 
stored in amber glass bottles at 4-8°C and brought up to room temperature prior to testing 
with the aid of a water bath.   Solutions were made fresh every five days.  Millipore™ 
filtered di water was used as the blank stimulus and the rinsing agent in all experiments. 
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Intensity matching protocol:  Bitter taste among individuals is highly variable (see the 
range of concentrations required to elicit moderate bitterness in Table 1); what one 
individual perceives as weak bitterness, another may perceive as extremely bitter.  In this 
research we fixed the perceived initial bitterness intensity (allowing individual 
concentrations of pharmaceuticals to vary) rather than fix the concentration of 
pharmaceuticals (allowing individual perceptual intensities to vary).  This allowed us to 
compare whether a bitterness blocker was effective for all individuals, as well as to make 
fair comparisons of a blocker’s efficacy from bitter pharmaceutical to bitter 
pharmaceutical.   
The intensity matching procedure involved adjusting the concentrations until each 
subject rated the bitter intensity of every bitter stimulus as “moderate” on the LMS.   The 
tasting protocol was whole mouth sip and spit.  On each trial, subjects held 10mls of 
solution in their mouth for five seconds and rated the taste qualities of the solution, prior 
to expectorating.  Subjects wore nose-clips to eliminate olfactory input in this phase as 
well as the cation and anion salt series experiments.  Subjects rated the bitter intensity of 
predetermined concentrations of pharmaceuticals (10mM pseudoephedrine, 4mM 
ranitidine, 50mM acetaminophen, 0.1mM quinine, 1.2M urea).   Bitter taste intensity was 
recorded on a computerized LMS and transferred in real time via a printer to the 
technician making the solutions who altered the concentration of solutions up or down 
depending on the individual subject’s response.  The new solution was tasted and rated 
by the subject, and depending on the response, new concentrations were made until the 
bitter intensity was rated as “moderate”.  There was an interstimulus interval of 
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approximately 60 sec, during which time the subject was required to rinse their mouth 
with di water at least 4 times.  As a test for successful matches, subjects were required to 
rate the intensity of the bitter compound as “moderate” on the LMS when randomly 
presented with a “matched” bitter stimulus during a separate test session.  If the LMS 
rating did not match “moderate” (16±4) allowing 25% variability during the test re-
evaluations of the matched intensities, the subject was either retested again or excluded 
from the study after failing three retests for lack of reliability.  Human sensory ratings are 
highly variable.  If we limited the variability to 10% (16±1.6) we would eliminate most 
subjects.  Four of 21 subjects screened were excluded from the study by the 25% 
criterion.  Mean and range of concentrations of pharmaceuticals determined in the 
intensity matching phase to elicit “moderate” bitterness are listed in Table I. 
 
Cation protocol:  Solutions of pharmaceuticals were prepared for each subject at the 
concentration individually assessed in the intensity-matching phase.  Because acetate 
reduces the perceived saltiness of cations relative to when they are associated with 
chloride (13), acetate was the fixed anion in the cation series.  The acetate salts (100mM): 
NaAc, NH4Ac, MgAc, KAc, CaAc, and an equal molar cation combination of the five 
cations (COMAc, 20mM of each cation giving a 100mM cation cocktail) were added to 
the pharmaceutical solutions.   As experimental controls, subjects were presented with: 
cations without pharmaceuticals, pharmaceuticals without cations, and di water as a 
blank.  Each of six sessions was comprised of the pharmaceuticals in combination with 3 
cations and the controls.  All samples were presented in random order with an 
interstimulus interval of 2 min.  Subjects rated five taste qualities (sweet, sour, bitter, 
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salty, savory), each with its own screen on a computerized LMS.  All cation-
pharmaceutical combinations were presented in triplicate on separate test days as a test of 
reliability.  All subjects participating in the experiment completed the cation phase prior 
to starting the anion phase. 
 
Anion protocol:  The general protocol was the same as described in the cation experiment 
above.  There were twelve anions used in this experiment: MSG, NaAMP, NaCl, NaSal, 
NaGlc, Na2GP, Na2Phos, NaProp, Na2SO4, NaI, and an equal molar anion combination of 
five anions (COM, 20mM of each anion MSG, NaCl, NaGlc, NaSal, and NaI giving a 
100mM anion cocktail), were added to the pharmaceutical solutions.  Potassium iodide 
(KI) was also included as a control for NaI to further assess the impact of the iodide 
anion on bitterness.  Because sodium is a highly effective bitterness blocker it was the 
fixed cation in the anion salt series and all solutions were prepared to have 0.1N sodium.  
The objective was to determine whether any anions had bitterness blocking efficacy 
complimentary to sodium.  Na2Phos, Na2GP, and Na2SO4 were all disodium salts 
therefore were prepared at 50mM.  As the pH of salt solutions were variable, a 10mM 
potassium phosphate buffer (pH 6.6) was added to all solutions, which ensured solutions 
were within 0.6 pH units of neutrality with the exception of NaAMP which was pH 5.  
Buffer concentrations above 10mM started to have a perceivable taste, whereas 10mM 
potassium phosphate buffer had no effect on taste quality of solution (results not shown).   
 
Analysis:  Data were expressed as arithmetic means ± SE.  Student t-tests with Bonferroni 
corrected (p value divided by the number of t-tests performed) criteria for significance 
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were performed on percent bitterness inhibition data from subjects to examine any 
differences among cations (p<0.05/15 = p<0.003), among anions (p<0.05/45 = p<0.001) 
and the iodide salts (p<0.05/2 = p<0.025).  Statistical significance of individual 
pharmaceutical cation/anion interaction was determined by 1 or 2 way analysis of 
variance (ANOVA) using the Statistica 4.5 package.  Post-hoc pairwise comparisons 
were conducted with the Scheffé test.  For the ANOVA’s, p values <0.05 were 
considered statistically significant.  All correlations were performed using Pearson’s 
product moment matrix correlation.   
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Results 
CATION INFLUENCE ON BITTERNESS 
Results:  The major taste associated with the various anions was: NaAc primarily salty, 
COMAc and KAc encompassed all tastes to varying extents, NH4Ac was perceived to 
have all taste qualities except sweetness, MgAc was primarily sour with sweet and bitter 
qualities, and CaAc was primarily bitter with salty and sour qualities.  Taste profiles of 
salt and pharmaceutical mixtures showed the major effect was a reduction of bitterness of 
the pharmaceuticals.  Therefore, the following analysis concentrated on bitter taste. 
There were significant differences among the cations overall bitterness inhibition 
properties on the pharmaceuticals (Figure 2).  NaAc (55%) was significantly more 
effective at inhibiting bitterness than NH4Ac (36%, p<0.003), MgAc (34%, p<0.003) & 
KAc (33%, p<0.003), and CaAc (18%, p<0.003), but not COMAc (42%) which contains 
20mM sodium.  All cations significantly (p<0.003) inhibited bitterness more than CaAc.  
There were no significant differences in bitterness inhibition among the cations COMAc, 
NH4Ac, MgAc and KAc. 
Figure 3 shows the mean bitter intensity ratings, standard error and significant 
differences for the five pharmaceuticals alone and in binary mixture with NaAc, COMAc, 
NH4Ac, MgAc, KAc, and CaAc.  The mean individual bitter intensities were analyzed by 
a 5 x 7 (pharmaceutical x cation) repeated measures ANOVA. 
There was a significant main effect of the bitterness of the different 
pharmaceuticals without salts [F(4,64) = 4.04, p<0.05], indicating the initial bitterness of 
pharmaceuticals was different.  Subjects rated pseudoephedrine as significantly more 
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bitter than quinine (p<0. 05), but still within the established criteria for “moderate”.  
Also, there was a significant main effect among the pharmaceuticals and their 
susceptibility to suppression by the cations [F(4,64) = 3.08, p<0.05] (Figure 3).   
There was a significant interaction among the pharmaceuticals and cations 
[F(24,384) = 3.03, p<0.001].  Thus, there was variation among individual cation’s ability 
to inhibit the bitterness of various pharmaceuticals with the exception of KAc (compare 
columns in Figure 3).  NaAc inhibited the bitterness of ranitidine (73%) significantly 
more than the bitterness of quinine (36%, p<0.05) or pseudoephedrine (51%, p<0.05).  
And NH4Ac inhibited the bitterness of ranitidine (61%) more than the bitterness of 
pseudoephedrine (26%, p<0.05).   
Similarly, the bitterness of individual pharmaceuticals was differentially affected 
by the various cations (compare across rows in Figure 3).  MgAc was the most effective 
cation at inhibiting the bitterness of quinine, whereas NaAc was the most effective cation 
for all other pharmaceuticals.  NaAc was the only cation to significantly inhibit urea’s 
bitterness (55%), which supports previous research investigating sodium’s influence on 
urea (13).   CaAc was the only cation not to significantly inhibit the bitterness of any 
pharmaceutical.   
The susceptibility of selected bitter compounds to inhibition by salts were highly 
correlated.  For example, the bitterness inhibition of acetaminophen and urea by the salts 
COMAc, NH4Ac, MgAc, KAc, CaAc (r2=0.93, p<0.001; r2=0.42, p<0.05; r2=0.8, 
p<0.001; r2=0.55, p<0.05; r2=0.93, p<0.001, respectively) were strongly correlated. 
There were no significant correlations between bitterness inhibition efficacy of 
cations and physical parameters of the cations: molecular weight (r2=0.41), log P value 
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(r2=0.48), enthalpy (r2=0.43), entropy (r2=0.16) and Gibbs energy of formation (r2=0.36).  
Also, there was no relationship between bitterness inhibition efficacy of cations and 
Hofmeister series rank position. 
 
ANION INFLUENCE ON BITTERNESS 
Results:  The major taste associated with the various anions was: MSG, savory; NaAMP, 
sour; NaCl, salty; NaSal, sweet; NaI and KI, bitter.  All other anions had multiple taste 
qualities (24).  Anions such as NaSal and NaProp have negligible saltiness, in fact only 
NaCl and NaGlc could be said to have salty as their dominant taste quality.  As in the 
cation experiment, the taste profile of the anions was only slightly altered when mixed 
with the pharmaceuticals, the major change was an inhibition of bitterness of the 
pharmaceuticals, therefore the following analysis focused on bitter taste. 
The iodide salts, NaI and KI enhanced the bitterness of the pharmaceuticals.  
Therefore, both were analyzed separately from the anions that inhibited bitterness in 
order to reduce variability within the analyzed data sets.   
Overall there were significant differences in bitterness inhibiting properties 
among the anions (Figure 4).  Both MSG and NaAMP (both 67%) were significantly 
(p<0.001) more effective at inhibiting bitterness across all pharmaceuticals than NaCl 
56%, NaGlc 53%, Na2GP 49%, Na2Phos 48%, NaProp 47%, COM 46% and Na2SO4 
33%.  With the exceptions of NaProp and COM, all other anions significantly (p<0.001) 
inhibited bitterness more than Na2SO4.  There were no significant differences in 
bitterness inhibition among the anions NaCl, NaSal, NaGlc, Na2GP, Na2Phos, NaProp, 
and COM. 
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The mean bitterness intensity ratings, standard error and significant differences 
for the five pharmaceuticals in mixture with MSG, NaAMP, NaCl, NaSal, NaGlc, 
Na2GP, Na2Phos, NaProp, COM and Na2SO4 are shown in Figure 5.  The mean 
individual bitter intensities were analyzed by a 5 x 11 (pharmaceutical x anion) repeated 
measures ANOVA.   
There was no significant difference in the initial bitterness of pharmaceuticals 
because the intensity matched concentration of pseudoephedrine was re-evaluated after 
the cation experiment, and decreased by 10% for every subject.  Mean initial bitter 
intensities of pharmaceuticals from both the cation and anion experiment were analyzed 
by a 5 x 2 (pharmaceutical x experiment) repeated measures ANOVA: there was no 
significant difference between the bitterness levels in the cation and anion experiments 
[F(1,16) = 3.04, p=0.1].   
There was a significant pharmaceutical x anion interaction [F(40,520) = 1.50, 
p<0.05], indicating that there were differences among individual anions and their effects 
on individual pharmaceuticals (Figure 5).   
As in the cation experiment, there was significant variation with an individual 
anion’s bitterness inhibiting efficacy of various pharmaceuticals: NaSal inhibited the 
bitterness of quinine (71%) significantly more than it did the bitterness of 
pseudoephedrine (41%) (p<0.05).  And MSG tended to suppress the bitterness of 
ranitidine (88%) more than it did the bitterness of pseudoephedrine (57%) (p=0.063).  
Both the iodide anions significantly (p<0.025) increased bitterness across all of 
the pharmaceuticals, NaI 18% and KI 26%.  Post-hoc analysis showed (Table II) 
interactions between the iodide salts and individual bitter compounds and the only 
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significant increase in bitterness with a single compound was the addition of KI to urea 
(42%, p<0.05).   
There were no statistically significant correlations (p<0.05) between bitterness 
inhibition efficacy of anions and physical parameters of the anions: molecular weight 
(r2=0.04), log P value (r2=0.48), enthalpy (r2=0.05), entropy (r2=0.07), and Gibbs energy 
of formation (r2=0.04).  There was no correlation between bitterness inhibition efficacy of 
anions and Hofmeister series rank position. 
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Discussion 
Sodium’s bitter inhibiting properties 
Overall sodium was significantly the most effective cation at inhibiting bitterness 
of the pharmaceuticals.   The effect of the sodium cation on taste has been reported in the 
psychophysical literature (13, 14, 16, 25--30), including sodium’s effect as a bitterness 
inhibitor for compounds such as quinine and urea (13--16, 25, 31).  Sodium ions inhibit 
bitterness in the periphery, acting on oral physiology, rather than in the brain by a 
cognitive interaction of perceived saltiness on bitterness.  Evidence for this comes from 
the observation that sodium salts with little salty taste are equally effective at blocking 
bitterness as highly salty sodium salts (13, 15).  The site of sodium’s action in the 
periphery is unknown, but Keast (32) proposed 4 potential sites or modes of action for 
sodium inhibiting bitterness within the peripheral taste system: 1/ shielding of the 
receptor protein from bitter compounds, 2/ moderating or modulating ion channels or 
pumps, 3/ stabilizing the cell membrane, 4/ interfering with second messenger systems 
after entering receptor cells.  Whatever sodium’s mode of action, its ability to suppress 
bitter taste is superior to that of other cations tested in this study. 
 
MSG and AMP bitter inhibiting properties 
The anions were not neutral partners to sodium in blocking bitterness.  MSG and 
NaAMP were significantly more effective at inhibiting bitterness of the pharmaceuticals 
than the other anions tested, which indicates an active role of the anion in bitterness 
inhibition.  Psychophysical and electrophysiological research showed that the glutamate 
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anion inhibits bitterness (18, 33); however, the bitter blocking mode of action of 
glutamate is also unknown.  The mechanisms of bitterness blocking by NaAMP are also 
unknown.  In this study, we found commonality between MSG and NaAMP in regard to 
taste quality (savory) and bitter inhibiting properties, raising the possibility that these 
compounds share transduction components in the peripheral taste system.   
Even though MSG (and NaAMP) exhibited superior bitterness inhibition in 
comparison to other anions tested, their associated savory taste may make them suitable 
in only a subset of formulations.  Pharmaceutical flavorists may have to try low 
concentrations of MSG (or NaAMP) to find the minimum concentration that will inhibit 
bitterness.   
 
Differential inhibition of bitterness 
Certain cations and anions exhibited specific inhibition of bitterness for selected 
pharmaceuticals.  NaAc and NH4Ac significantly inhibited the bitterness of ranitidine 
more than that of pseudoephedrine, while NaSal significantly inhibited quinine bitterness 
more than that of pseudoephedrine.  Differential inhibition of bitterness may help 
elucidate receptors/mechanisms involved in bitter taste, as these interactions suggest that 
the cations/anions affect a part of the bitter taste signal cascade that is specific to one 
pharmaceutical and not another.  Presumably, specificity of action of cations or anions is 
likely to occur at the receptor level, rather than downstream in the bitter signal cascade, 
since downstream events are likely to have more general effects.   The differential 
inhibition of bitterness exhibited by some cations and anions should be further 
investigated.  Pharmaceutical flavorists should explore a variety of salts to determine 
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which salt has superior bitterness inhibiting properties for a particular bitter compound.  
Additionally, flavorists should utilize Na+’s superior bitterness inhibiting properties and 
include it with the pharmaceutical formula when possible. 
 
Potassium and ammonium ions 
Not all cations differentially influenced bitterness; K+ had a general or non-
specific inhibitory effect on pharmaceutical bitterness.  This general inhibitory effect 
suggests that K+ affects a bitter taste mechanism(s) common to the pharmaceuticals 
employed in this study rather than having a specific mode of action at a receptor.   
The K+ and NH4+ cations have similar actions on in solution properties (34) and 
on cell membranes (35--37), while voltage clamp studies have shown differences 
between the two cations (38).  In the present study, there were similarities between K+ 
and NH4+ with regard to bitter inhibition for the pharmaceuticals.  Neither salt 
significantly inhibited the bitterness of pseudoephedrine or urea, while both significantly 
inhibited the bitterness of ranitidine, acetaminophen and quinine.  However, NH4Ac and 
KAc’s ability to inhibit ranitidine’s bitterness were not identical.  There was a significant 
difference between NH4Ac and CaAc when inhibiting ranitidine bitterness, but KAc did 
not significantly differ from CaAc.  And NH4Ac inhibited ranitidine and pseudoephedrine 
to different degrees while KAc inhibited their bitterness similarly.  
 
Combined cations 
 Two combinations of salts, one cation mixture (COMAc) and one anion mixture 
(COM), were assessed as bitterness inhibitors in this study.  There was no significant 
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difference between the bitterness blocking efficacy of NaAc and COMAc.  The cation 
combination inhibited bitterness 20% more than predicted if bitter inhibition was a linear 
relationship with concentration of salts (e.g. 1/5th Na’s inhibition + 1/5th NH4’s inhibition 
+ etc).  This result suggests that there may be synergy among the cations leading to 
enhanced bitterness inhibition, or it may mean that sodium’s concentration-bitterness 
inhibition function is hyperbolic and the 20mM sodium in the combined cation mixture 
has comparable bitterness blocking efficacy to the 100mM sodium.  To assess whether 
there was synergy, sodium’s concentration-bitterness inhibition functions would have to 
be generated for these pharmaceuticals to assess the bitterness blocking efficacy at low 
concentrations.  The combination of anions was closer to the value a linear relationship 
between anion concentration and bitterness blocking efficacy would predict, although the 
actual value was 9% above the predicted value.   
 
Hofmeister Series     
In this study we also tested the hypothesis that the chemical-bond structure 
making or breaking ability of salts, indicated by their Hofmeister series position, would 
influence their bitterness inhibiting properties.  The ranked Hofmeister series values for 
the cations (NH4+→K+→ Na+→ Mg2+→ Ca2+) and anions (SO42-→PO42-→Cl-→I-) did 
not correlate with bitterness inhibiting efficacy when examining the ion’s impact on each 
target compound.  Nor was the Hofmeister series predictive when averaging across bitter 
targets.  Therefore, we conclude that the chemical-bond structure making / breaking 
ability of cations and anions, does not predict bitterness inhibition in any obvious 
manner, based upon the stimulus set tested.   
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General comments 
In this research, each subject was given their own unique set of pharmaceutical 
concentrations in order to match the perceived bitterness across all subjects and all 
pharmaceuticals.  This was done because bitter taste sensitivity is highly variable among 
individuals.  In practice, however, the population receives a fixed concentration of a 
pharmaceutical in formulation.  This means that some will perceive a formulation to be 
highly bitter and others will find it barely bitter.  By fixing perceived bitterness across 
individuals in the present study, we have shown that we can inhibit bitterness with 
selected salt-pharmaceutical combinations for all tasters. 
Overall the bitterness of these common over-the-counter pharmaceuticals could 
be inhibited by mixture with salts.  Sodium and glutamate and AMP were the most 
effective ions at inhibiting bitterness.  The salts are safe and effective at low 
concentrations, and should be applicable in pediatric and adult liquid formulations and 
should increase compliance with prescribed regimens with bitter pharmaceuticals. 
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Abbreviations 
NaAc = sodium acetate  
COMAc = combined cations (NaAc, NH4Ac, MgAc, KAc, CaAc)  
NH4Ac = ammonium acetate  
MgAc = magnesium acetate 
KAc = potassium acetate  
CaAc = calcium acetate 
MSG = monosodium glutamate 
NaAMP = adenosine monophosphate  
NaCl = sodium chloride 
NaSal = sodium salyiclate 
NaGlc = sodium gluconate 
Na2GP = di-sodium glycerophosphate 
Na2Phos = di-sodium phosphate 
NaProp = sodium propionate  
COM = combined anions (MSG, Cl, Glc, Sal, I)  
Na2SO4 = di-sodium sulfate  
NaI = sodium iodide 
KI = potassium iodide. 
PHCL=pharmaceutical 
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Tables 
 
Table I  Average molarity and range of molarity of target compounds as 
assessed in the intensity matching experiment 
 mM Range 
Pseudoephedrine 10.7±5.3 1-25 
Ranitidine 3.5±1.7 1-7 
Acetaminophen 43.8±13.4 24.8-62.3 
Quinine 0.24±0.27 0.06-0.9 
Urea 1500±800 400-2800 
 
± standard deviation 
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Table II  Influence of iodide salts on bitterness intensity of 
pharmaceuticals 
 No salt NaI KI 
Pseudoephedrine 15.7±1.0 18.5±0.4 17.9±0.4 
Ranitidine 14.9±1.4 16.3±0.5 18.5±0.4 
Acetaminophen 14.5±1.4 17±0.7 18.7±0.4 
Quinine 15.7±0.9 18.5±0.6 17.9±0.5 
Urea 14.4±1.2 17.7±0.5 20.5*±0.4 
 
* significant difference (p<0.05) in bitterness between bitter compounds and bitter compounds with anion 
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Legends for Figures 
Figure 1 Hofmeister series of cations and anions 
The Hofmeister series of salts are sequenced, in part, according to their 
electronegativity at moderate concentrations (10mM to 1M) and neutral 
pH, and their ability to alter the structure of pure water and/or proteins 
 
Figure 2 Cations ability (%) to inhibit bitterness of pharmaceuticals 
The x-axis represents salt-pharmaceutical mixtures. Abbreviations of 
acetate salts (100mM) are: NaAc = sodium acetate, COMAc = combined 
cations (NaAc, NH4Ac, MgAc, KAc, CaAc), NH4Ac = ammonium 
acetate, MgAc = magnesium acetate, KAc = potassium acetate and CaAc 
= calcium acetate.  The y-axis represents the % inhibition of bitterness for 
each salt averaged across all five pharmaceuticals.  Different letters 
symbolize a statistically significant (p<0.003) difference in bitterness 
inhibition efficacy between cations.  Error bars represent standard errors.   
 
Figure 3 Specific effects of cations on bitterness of pharmaceuticals 
Each panel represents one bitter compound.  The Y-axis represents 
average bitterness rating on the Labeled Magnitude Scale (mean±SE) and 
the X-axis lists the solutions tested.  Abbreviations for pharmaceuticals are 
PSD=pseudoephedrine, RTD=ranitidine, ACN=acetaminophen, 
QHCl=quinine.  Abbreviations of salts are the same as in Figure 2.  
Concentrations of salts are the same as Figure 2.  The bar representing 
bitterness of the pure bitter compound is indicated by PHCL 
(pharmaceutical) on the X axis. Hatched bars indicate a significant 
(p<0.05) reduction in bitterness when the cation was added to the 
pharmaceutical relative to PHCL.   Corresponding letters above bars 
indicate differences in bitterness among cation-pharmaceutical mixtures.  
Within rows or columns, any bars that share a letter in common are 
different at the level indicated (a,b,c,d,e,f,g,h,i,j p<0.05; z,y,x,w p<0.1).   
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Figure 4 Anions ability (%) to inhibit bitterness of pharmaceuticals 
The axes are the same as Figure 2 except different salts are represented.  
Abbreviations for sodium salts (0.1N Na) are: MSG = monosodium 
glutamate, AMP = adenosine monophosphate, Cl = sodium chloride, Sal = 
sodium salicylate, Glc = sodium gluconate, GP = di-sodium 
glycerophosphate, Phos = di-sodium phosphate, Prop = sodium 
propionate, COM = combined anions (MSG, Cl, Glc, Sal, I), SO4 = di-
sodium sulfate, I = sodium iodide, and KI = potassium iodide.  Different 
letters symbolize a statistically significant (p<0.001) difference in 
bitterness inhibition efficacy between anions.  Error bars represent 
standard errors.   
 
Figure 5 Specific effects of anions on bitterness of pharmaceuticals 
Each panel represents one bitter compound.  The Y-axis represents 
average bitterness rating on the Labeled Magnitude Scale (mean±SE), and 
the X-axis lists the solutions tested.  Abbreviations are the same as in 
Figures 3 & 4.  The bar representing bitterness of the pure bitter 
compound is indicated by PHCL (pharmaceutical) on the X axis.  
Concentrations of salts were the same as Figure 4.  Hatched bars indicate a 
significant (p<0.05) reduction in bitterness when the anion was added to 
the pharmaceutical relative to PHCL.   Corresponding letters above bars 
indicate differences in bitterness among anion-pharmaceutical mixtures.  
Within rows or columns, any bars that share a letter in common are 
different at the level indicated (a,b,c p<0.05; z,y,x,w p<0.1).   
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Hofmeister series of ions in order of their affect at chemical-
bond interfaces 
 
Anions 
F-,  PO43-,  SO42-,  CH3COO-,  Cl-       Br-,  I-,  CNS- 
 
Cations 
(CH3)4N+,  (CH3)2NH2+,  NH4+,  K+, Na+     Cs+, Li+,  Mg2+,  Ca2+, Ba2+ 
 
Type of Chemical Interaction
Stabilizing chemical 
bond strength 
Destabilizing chemical 
bond strength 
Bond Forming Bond Breaking 
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